Digital Look

Welcome to Digital Look++,
you are not logged in

Hemogenyx Pharmaceuticals (HEMO)

Pharma and Biotech

627.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Jun-25	Interim	n/a	(5.01)	(0.83)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	n/a	(2.10)	(200.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	n/a	(5.11)	(280.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	n/a	(3.99)	(200.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	n/a	(6.70)	(94,800.00)p	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	n/a	(5.63)	(181.10)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts data is not available for this company.

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.